BioCentury
ARTICLE | Company News

Cleveland BioLabs, Roswell Park Cancer Institute deal

January 22, 2007 8:00 AM UTC

CBLI will receive about $3 million from the institute and up to $2 million from other New York state agencies toward development of the company's CBLC 102 to treat cancer and CBLB 502 and CBLB 612, to treat cancer side effects. CBLC 102, which is in the curaxin family of compounds that target p53 and NF-kappa B, is in a Phase II trial to treat hormone refractory prostate cancer. CBLB 502 and CBLB 612 are preclinical radioprotectants. ...